Oncogenic driver mutations frequently occur in lung cancer and play role in carcinogenesis.
These mutations are usually associated with distinct clinical and histological features and …

The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been
evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver …

Precision oncology is now the evidence-based standard of care for the management of
many advanced non-small cell lung cancers (NSCLCs). Expert consensus has defined …

Over the past decade, a multitude of targeted agents have been explored in the treatment of
advanced non–small cell lung cancer (NSCLC). Thus far, two broad classes of agents have …

In recent years, there has been a major paradigm shift in the management of non-small cell
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …

Non-small cell lung cancer (NSCLC) accounts for approximately 80–85% of all cases of lung
cancer, and it is the most common cause of death in men and second only to breast cancer …

Lung cancer is the most common malignancy in the US and causes the most cancer-related
deaths. Non-smallcell lung carcinoma (NSCLC) accounts for the majority of cases. NSCLC …

Abstract Purpose of Review Over the last two decades, the identification of targetable
oncogene drivers has revolutionized the therapeutic landscape of non-small cell lung …

In 2018 research in the field of advanced NSCLCs led to an expanded reach and impact of
immune checkpoint inhibitors (ICIs) as part of a frontline treatment strategy, regardless of …

Therapy for advanced non-small-cell lung cancer has developed significantly with new
awareness of histologic subtype as an important factor in guiding treatment and the …